SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Discover recent findings that indicate that c-Rel expression is upregulated in psoriatic skin lesions and decreases following treatment.

This fuels the excessive immune response typical of psoriasis. With the key role of SSAT in the inflammatory process, the ...

A potential new psoriasis treatment restores the function of certain anti-inflammatory immune cells in a targeted manner.

A protein called NF-kB c-Rel has been found to intensify the symptoms of psoriasis, offering a potential new target for ...

A team of skin disease specialists has found that a derivative of the diuretic drug benzamil can be used to block key inflammatory pathways in psoriasis mouse models. In their paper published in ...

"Psoriasis can be a challenging condition to manage due to long-term treatments with various side effects. SFA-002's effect in the imiquimod-induced mouse model is compelling. The results ...